These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28096973)

  • 1. A fission yeast cell-based system for multidrug resistant HIV-1 proteases.
    Benko Z; Liang D; Li G; Elder RT; Sarkar A; Takayama J; Ghosh AK; Zhao RY
    Cell Biosci; 2017; 7():5. PubMed ID: 28096973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (
    Zhang J; Vernon K; Li Q; Benko Z; Amoroso A; Nasr M; Zhao RY
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34202872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Protease in the Fission Yeast Schizosaccharomyces pombe.
    Benko Z; Elder RT; Li G; Liang D; Zhao RY
    PLoS One; 2016; 11(3):e0151286. PubMed ID: 26982200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
    Benko Z; Zhang J; Zhao RY
    Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.
    Yang H; Nkeze J; Zhao RY
    Cell Biosci; 2012 Sep; 2(1):32. PubMed ID: 22971934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of HIV-1 genome in fission yeast Schizosaccharomyces pombe.
    Nkeze J; Li L; Benko Z; Li G; Zhao RY
    Cell Biosci; 2015; 5():47. PubMed ID: 26309721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
    Weber J; Mesters JR; Lepsík M; Prejdová J; Svec M; Sponarová J; Mlcochová P; Skalická K; Strísovský K; Uhlíková T; Soucek M; Machala L; Stanková M; Vondrásek J; Klimkait T; Kraeusslich HG; Hilgenfeld R; Konvalinka J
    J Mol Biol; 2002 Dec; 324(4):739-54. PubMed ID: 12460574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model.
    Zhang J; Li Q; Kawashima SA; Nasr M; Xue F; Zhao RY
    Pathogens; 2022 Jul; 11(7):. PubMed ID: 35890048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
    Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV-1 protease variants.
    Nayak C; Chandra I; Singh SK
    J Cell Biochem; 2019 Jun; 120(6):9063-9081. PubMed ID: 30506751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1.
    Inoue M; Oyama D; Hidaka K; Kameoka M
    FEBS Open Bio; 2017 Jan; 7(1):88-95. PubMed ID: 28097091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
    Nakashima M; Ode H; Suzuki K; Fujino M; Maejima M; Kimura Y; Masaoka T; Hattori J; Matsuda M; Hachiya A; Yokomaku Y; Suzuki A; Watanabe N; Sugiura W; Iwatani Y
    Front Microbiol; 2016; 7():61. PubMed ID: 26870021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.